Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 11 Apr 2025
A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer resistance to enzalutamide, a frequently used drug. The article is published in Science Signaling.
Read Full NewsThe HCPFive: Top News for Healthcare Providers from the Week of 10/25
Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab
A secondary analysis found the SWIFT accelerated protocol eased suicidal ideation faster than standard daily deep TMS dosing in major depressive disorder.
Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.
Here's some of what is coming soon to NeurologyLive® this week.
Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.
ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know
1.
A US health panel advises starting mammograms at age 40 rather than 50.
2.
Trial Challenges Indefinite Maintenance for Multiple Myeloma
3.
Nasal therapeutic HPV vaccine could prevent cervical cancer
4.
Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC
5.
Six breast texture patterns linked to higher risk of invasive cancer
1.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
2.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
3.
Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care
4.
All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment
5.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
5.
Understanding Cancer: Early Detection and Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge